CRISPR/Cas 9 gene technology provides an opportunity to profoundly manipulate cells for a more efficient and effective T-cell therapy.
About the Study
This landmark clinical trial, expected to be the first U.S. study to involve CRISPR/Cas9 in humans, will use this technology to modify T-cells so that they can fight cancer. The types of cancer in the study include melanoma, sarcoma and multiple myeloma.
The University of Pennsylvania is leading the study, also expected to open at the University of California, San Francisco, and The University of Texas MD Anderson Cancer Center.
The Parker Institute for Cancer Immunotherapy is in part providing funding for this study.
The trial opened at the University of Pennsylvania in early 2018.